Macquarie Group
CRNX icon

Macquarie Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Macquarie Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,908
Closed -$1.51M – 1670
2025
Q1 		$1.51M Sell
44,908
-303
-0.7% -$11.3K ﹤0.01% 1314
2024
Q4 		$2.31M Sell
45,211
-401
-0.9% -$22.4K ﹤0.01% 1155
2024
Q3 		$2.33M Buy
+45,612
New +$2.35M ﹤0.01% 1183
2022
Q4 		– Sell
-3,138
Closed -$62K – 1841
2022
Q3 		$62K Hold
3,138
– – ﹤0.01% 1893
2022
Q2 		$59K Hold
3,138
– – ﹤0.01% 2007
2022
Q1 		$69 Buy
+3,138
New +$63.5K ﹤0.01% 2041

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group's CRNX Position: Q2 2025 in Review

Macquarie Group sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 44,908 shares — an estimated $1.51M sold.

Macquarie Group first reported a position in CRNX in Q1 2022 and held it in 6 quarters. The position peaked at $2.33M in Q3 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Macquarie Group reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Macquarie Group sold 44,908 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $1.51M.
  • Macquarie Group first reported a position in Crinetics Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Macquarie Group's Crinetics Pharmaceuticals position peaked at $2.33M in Q3 2024.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Macquarie Group's 13F filing for Q2 2025, filed 14 Aug 2025.